SCHEMBL15545878

SCHEMBL15545878

COc1ccc(C(=O)c2cc(CC(=O)O)c(-c3ccc(Cl)cc3)s2)cc1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.75
MEN1 O00255 1/20 0.75
KMT2A Q03164 1/20 0.75
MAPT P10636 4/20 0.53
HPGD P15428 2/20 0.51
PTGDR2 Q9Y5Y4 3/20 0.49
AKR1C4 P17516 1/20 0.47
PTGS1 P23219 1/20 0.47
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.43
OPRD1 P41143 1/20 0.43
ADORA1 P30542 1/20 0.42
PPARD Q03181 1/20 0.42
TP53 P04637 1/20 0.42
ALOX5 P09917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15545703 0.94 RXFP1 (0.69) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15545766 0.90 MEN1 (0.61) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15546759 0.90 KMT2A (0.66) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15545929 0.90 MEN1 (0.63) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15547777 0.89 MEN1 (0.60) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL16907765 0.89 RXFP1 (0.66) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15546009 0.89 KMT2A (0.66) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15545762 0.89 RXFP1 (0.62) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15546980 0.88 RXFP1 (0.71) RXFP1MEN1KMT2AMAPTHPGD
SCHEMBL15547033 0.88 MEN1 (0.65) RXFP1MEN1KMT2AMAPTPTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US claimed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP claimed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US claimed
CN-104718200-A Thiophene derivatives used in the treatment of diabetes METABRAIN RES 2015-06-17 CN claimed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP claimed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO claimed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
CN-104718200-A Thiophene derivatives used in the treatment of diabetes METABRAIN RES 2015-06-17 CN disclosed
EP-2875010-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES Metabrain Research (FR) 2015-05-27 EP disclosed
WO-2014013181-A1 THIOPHENE DERIVATIVES USED IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2014-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT RXFP1 3837/4885MEN1 4184/4885KMT2A 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.